122

Hozirgi pandemiya va o‘tkir nafas olish sindromi (SARS-CoV-2) butun dunyo bo‘ylab o‘limga olib keldi. Bugungi kunda vafot etganlar soni 4,55 milliondan oshdi. SARS-CoV-2 infeksiyasini qo‘shimcha samarali davolash uchun dori-darmonlarni aniqlash uchun hujayra asosiy virus kirish retseptorlari bo‘lgan angiotenzin aylantiruvchi ferment 2 (ACE2) dimerizatsiyasini o‘lchash uchun ekran yaratildi. Bu ekran fenofibratning faol metaboliti bo‘lgan fenofibrik kislotani aniqladi. Fenofibrin kislota, shunigdek, virusli oqsilning retseptorlari bilan bog’lanish sohasini (RBD) beqarorlashtirdi va ferment bilan bog’liq immunoferment taxlilida RBD ning ACE2 ga bog’lanishi aniqlandi. Fenofibrat va fenofibrin kislota ikkita mustaqil laboratoriya tomonidan sinovdan o‘tkazilgan. Ikkala holatda ham, preparatning klinik dozalarda konsentratsiyasida fenofibrat va fenofibrin kislota virusli infeksiyani 70% gacha kamaytirdi. Keng klinik anamnez va nisbatan yaxshi xavsizlik profiliga ega keng bo‘lgan holda, ushbu tadqiqot fenofibratni gipertenziya va tana massasi indeksi yuqori bo‘lgan bemorlarda SARS-CoV-2 infeksiyasini davolash uchun klinik baholashni talab qiladigan potensial terapevtik vosita sifatida aniqlaydi. 

  • Ўқишлар сони 122
  • Нашр санаси 15-03-2022
  • Мақола тилиO'zbek
  • Саҳифалар сони9-12
Ўзбек

Hozirgi pandemiya va o‘tkir nafas olish sindromi (SARS-CoV-2) butun dunyo bo‘ylab o‘limga olib keldi. Bugungi kunda vafot etganlar soni 4,55 milliondan oshdi. SARS-CoV-2 infeksiyasini qo‘shimcha samarali davolash uchun dori-darmonlarni aniqlash uchun hujayra asosiy virus kirish retseptorlari bo‘lgan angiotenzin aylantiruvchi ferment 2 (ACE2) dimerizatsiyasini o‘lchash uchun ekran yaratildi. Bu ekran fenofibratning faol metaboliti bo‘lgan fenofibrik kislotani aniqladi. Fenofibrin kislota, shunigdek, virusli oqsilning retseptorlari bilan bog’lanish sohasini (RBD) beqarorlashtirdi va ferment bilan bog’liq immunoferment taxlilida RBD ning ACE2 ga bog’lanishi aniqlandi. Fenofibrat va fenofibrin kislota ikkita mustaqil laboratoriya tomonidan sinovdan o‘tkazilgan. Ikkala holatda ham, preparatning klinik dozalarda konsentratsiyasida fenofibrat va fenofibrin kislota virusli infeksiyani 70% gacha kamaytirdi. Keng klinik anamnez va nisbatan yaxshi xavsizlik profiliga ega keng bo‘lgan holda, ushbu tadqiqot fenofibratni gipertenziya va tana massasi indeksi yuqori bo‘lgan bemorlarda SARS-CoV-2 infeksiyasini davolash uchun klinik baholashni talab qiladigan potensial terapevtik vosita sifatida aniqlaydi. 

№ Ҳавола номи
1 1. Agababyan I.R., Soleyeva S.Sh. Mesto statinov v kompleksnom lechenii SARS-CoV-2. Voprosi nauki i obrazovaniya №14 (139) 2021. s.70-80. 2. Karpov Yu.A. Effektivnost i bezopasPUTNIK).Kardiologiya. 2020;60(6). DOI: 10.18087/cardio.2020.6.n1226. r.15-29.Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383:2427-2438. 5. Arutiunov G.P., Tarlovskaya E.I., KoziolovaN.A., Boldina M.V., Batiushin M.M., Ametov A.S. etal. The agreed experts’ position of the Eurasian Association of Therapists on tactics of management of patients with comorbid pathology infected with SARS-CoV-2. Therapeutic Archive. 2020; 92(9). DOI: 10.26442/00403660.2020.09.000703. 6. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology. 2020;S0091674920307387. [Epub ahead of print]. DOI: 10.1016/j.jaci.2020.05.019 7. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology. 2020;S0091674920307387. [Epub ahead of print]. DOI: 10.1016/j.jaci.2020.05.019. 8. Clore J, Thurby-Hay L. Glucocorticoid-Induced Hyperglycemia. Endocrine Practice. 2009;15(5):469–74.DOI: 10.4158/EP08331.RAR8. Shono A, Mori S, Nakamura K, Yatomi A, Takada H, Tanaka H et al. Glucocorticoid-sensitive Paroxysmal Atrial Fibrillation, Sick Sinus Syndrome, and Mitral Regurgitation in a Patient with Malignant Rheumatoid Vasculitis. Internal Medicine (Tokyo, Japan). 2019; 58(21):3093–8. DOI: 10.2169/internalmedicine.3090-19. 9. Darmon P, Dadoun F, Boullu-Ciocca S, Grino M, Alessi M-C, Dutour A. Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. American Journal of Physiology-Endocrinology and Metabolism. 2006;291(5):E995–1002. DOI: 10.1152/ajpendo.00654.2005. 10. European Societyof Cardiology. ESC Guidancefor the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Lastup dated on April 2020. Av. at:https://www.escardio.org/Education/COVID-19-and Cardiology/ESC-COVID-19-Guidance. 11. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.Lancet 2020;396:467-478. 12. Gorabi AM, KiaieN, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T et al. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. Journal of Clinical Medicine. 2019; 8(12):2051. DOI: 10.3390 / jcm 8122051. 13. Irina Rubenovna Agababyan, Sitora Shahobovna Soleeva, Muyassar Gafurjanovna Mukhemedovа, Jamol Uzokov. Сondition of coronary arteries and change of lipid profile in coronary heart disease. Journal of critical reviews 2020 August .р.4719-4723. 14. Lindsey R. Baden, M.D., Hana M. El Sahly, M.D., Brandon Essink, M.D., Karen Kotloff, M.D., Sharon Frey, M.D., Rick Novak, M.D., David Diemert, M.D., Stephen A. Spector, M.D., Nadine Rouphael, M.D., C. Buddy Creech, M.D., John McGettigan, M.D., Shishir Khetan, M.D., et al.Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. for the COVE Study Group. February 4, 2021N Engl J Med 2021; 384:403-416.DOI: 10.1056/NEJMoa2035389. 15. Ludovico Cantuti-Castelvetri, Ravi Ojha , Liliana d. Pedro, Minou Djannatian, Jonas Franz , Suvi Kuivanen, Franziska Van der Meer, Katri Kalliotuğberk Kaya , Mikael Simons. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. SCIENCE•13 Nov 2020•Vol 370, Issue 6518•pp. 856-860•DOI: 10.1126/science.abd2985. 16. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiology. 2020; DOI: 10.1001/jamacardio.2020.1286. 17. Markus Hoffmann, Hannah Kleine Weber, Simon Schroeder, Nadine Kruger, Tanja Herrler, Sandra Erichsen, Tobias S.Schiergens, Georg Herrler, Nai-HueiWu, Andreas Nitsche, Marcel A. Müller, Christian Drosten, Stefan Pöhlmann, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.CellPress. Volume 181, Issue 2, 16 April 2020, Pages 271-280.e8. 18. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–4. DOI: 10.1016/S0140-6736(20)30628-0. 19. Merryn Voysey DPhil, Sue Ann Costa Clemens PhD, Shabir A Madhi PhD, Lily Y Weckx PhD, Pedro MFolegatti MD, Parvinder KAley PhD, Brian Angus MD, Vicky LBaillie PhD, Shaun LBarnabas PhD, Qasim EBhorat MSc, SagidaBibi PhD, Carmen Briner MBBCh, Paola Cicconi PhD, Andrea MCollins PhD, Rachel Colin-Jones MSc, Clare LCutland PhD, Thomas CDarton DPhil, Keertan Dheda FRCPCH, Peter Zuidewind. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Volume 397, Issue 10269, 9–15 January 2021, Pages 99-111. 20. Ministry of Health of Russian Federation. Temporary methodical recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-2019). Version 7 (03.06.2020). Moscow. Av.at:https://static0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf. 2020. 21. Renhong Yan , Yuanyuan Zhang , Yaning Li, Lu Xia , Yingying Guo , Qiang Zhou Structural basis for the recognition of SARS-CoV-2 by full-length human ACE22020 Mar 27; 367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4. 22. S A Meo, I A Bukhari, J Akram, A S Meo, D C Klonoff. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. European review for medical and pharmacological sciences 2021 Feb; 25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. 23. Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nature Reviews Immunology. 2020;20(5):271–2. DOI: 10.1038/s41577-020-0312-7. 24. Shlyakho E.V., Konradi A.O., Arutyunov G.P., Arutyunov A.G., Bautin A.E., Boytsov S.A. et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID -19 pandemic. Russian Journal of Cardiology. 2020; 25(3):129–48. DOI: 10.15829/1560-4071-2020-3-3801. 25. Soleeva S.Sh., Djabbarova N.M. Yarasheva Z.X. «Сlinical and functional condition of patients with stable angina pectoris on the background of long-term use of Atorvastatin» International scientific review of the problems and prospects of modern science and education, Boston. USA. December 25-26, 2019. Р.113-115. 26. Soleeva S.Sh., Djabbarova N.M., Muradov Sh.B. The state of diastolic dysfunction of the left ventricle in patients with myocardial infaRMSion. Journal of cardiorespiratory research 2020 vol.3, issue 1, pp.78-81.DOI http://dx.doi.org./10.26739/2181-0974-2020-3-16. 27. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & Growth Factor Reviews. 2020;53:38–42. DOI: 10.1016/j.cytogfr.2020.04.0022. World Health Organization. Clinical management of COVID-19. WHO Reference Number: WHO/2019-nCoV/clinical/2020.5. 2020. [Internet] 2020. Available at: https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19nost terapii statinami// Atmosfera. Novosti kardiologii, 2019. № 1. S. 3-12. 3. Krugliy L.B., Karpov Yu.A. Uluchsheniye prognoza bolnix s serdechno-sosudistoy patologiyey na fone povishennogo urovnya Sreaktivnogo belka: novie dannie ob effektax atorvastatina i rozuvastatina. // Atmosfera. Novosti kardiologii, 2016. № 2. 33-40. 4. Mareyev V.Yu., Orlova Ya.A., Pavlikova Ye.P., Matskeplishvili S.T., Krasnova T.N., Malaxov P.S., Samoxodskaya L.M., Mershina Ye.A.Sinitsin V.Ye., Mareyev Yu.V., Kalinkin A.L., Begrambekova Yu.L., Kamalov A.A. Puls-terapiya steroidnimi gormonami bolnix s Koronavirusnoy pnevmoniyey (COVID-19), sistemnim vospaleniyem i riskom venoznix trombozov i tromboemboliy (issledovaniye Y
Кутилмоқда